Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 11M | 11% |
| Gross Profit | -3.2M | 32.1% |
| Cost of Revenue | 14M | 3.3% |
| Operating expense | 43M | 0.2% |
| Net Income | -29M | 4.8% |
| EBITDA | -33M | 4.2% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 301M | 7.2% |
| Total Liabilities | 82M | 14.3% |
| Total Equity | 219M | 4.2% |
| Shares Outstanding | 54M | 2.6% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -39M | 93.4% |
| Cash from investing | 16M | 110.1% |
| Cash from financing | 12M | 3514.9% |
EPS
Financial Highlights for Eyepoint Pharmaceuticals in Q3 '24
Eyepoint Pharmaceuticals reported a revenue of 11M, which is a 11% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at -3.2M, marking a 32.1% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 14M, a -3.3% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 43M, showing a -0.2% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -29M, showing a 4.8% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -33M, showing a 4.2% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Eyepoint Pharmaceuticals with growth in revenue, gross profit, and net income.
